Clinical trial
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HCXT-2001 Tablets and HCXT-2001 Tablets(A) After Single Administration in Healthy Adult Participants.
NCT07792928 is registered in ClinicalTrials.gov with Shanghai Peptidstar Therapeutics Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HCXT-2001 Tablets and HCXT-2001 Tablets(A) After Single Administration in Healthy Adult Participants.
- Lead sponsor
- Shanghai Peptidstar Therapeutics Limited
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- October 14, 2026
- Completion date
- November 10, 2026
- Enrollment
- 40 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.